ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Patients With Advanced/Metastatic Solid Tumors
Sponsor: Adagene Inc
A PHASE1/PHASE2 clinical study on Advanced/Metastatic Solid Tumors, this trial is completed. The trial is conducted by Adagene Inc and has accumulated 11 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
Status: Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Jun 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Feb 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Feb 2022 [monthly]
Recruiting PHASE1
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Adagene Inc
For direct contact, visit the study record on ClinicalTrials.gov .